0001867096-24-000103.txt : 20240605
0001867096-24-000103.hdr.sgml : 20240605
20240605161811
ACCESSION NUMBER: 0001867096-24-000103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HALKUFF DAWN
CENTRAL INDEX KEY: 0001743658
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 241022227
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS
STREET 2: 180 N. LASALLE ST., STE. 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 871082097
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
4
1
wk-form4_1717618682.xml
FORM 4
X0508
4
2024-06-05
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001743658
HALKUFF DAWN
C/O XERIS BIOPHARMA HOLDINGS, INC.
1375 WEST FULTON STREET, SUITE 1300
CHICAGO
IL
60607
1
0
0
0
0
Common Stock
2024-06-05
4
A
0
50000
0
A
107500
D
Common Stock
5410
I
By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders.
/s/ Beth Hecht, as Attorney-in-Fact
2024-06-05